|
FOR IMMEDIATE RELEASE
Pharma DD launches premier issue under new owner,
Cambridge Healthtech Institute
Issue highlights “proof-of-concept” research activities to ensure
increased success in the pipeline
NEWTON, MA – May 24, 2006 – Cambridge Healthtech Institute (CHI), the leader in biomedical conference development and management, today announced that the premier issue of Pharma DD (Pharmaceutical Discovery & Development) magazine has been published and will make its first appearance at the upcoming World Pharmaceutical Congress this week in Philadelphia, PA. Adorned with a new name (formerly Pharmaceutical Discovery from
Advanstar), an updated subscriber base, solid editorial and a new spirit, Pharma DD rejoins the life sciences arena as CHI applies its expertise to technical and business publishing aimed at management and laboratory professionals.
Delivered as a 6x per year publication, Pharma DD will have a total qualified, direct request circulation of 40,000 subscribers who are actively involved in research and development within pharmaceutical, biotechnology, and research laboratory industries.
The publication will contain a stimulating mix of content: the latest news gathered by Pharma DD editorial and correspondents; features and case studies providing in-depth coverage of critical technical and business strategy issues from drug discovery through development and into commercialization; commentary from industry leaders.
“As CHI's first endeavor into publishing, I could not be more excited and optimistic about launching Pharma DD. This premier issue showcases CHI's expansive network of contacts in life sciences and delivers the kind of content that CHI has a reputation of providing.” says CHI president, Philips
Kuhl. “We look forward to building Pharma DD into the most widely read source of drug discovery and development solutions and information.”
Pharma DD’s premier issue, available online at
www.pharmaDD.com, features a special report, “Proof of Concept: Pharma’s New Watchwords”, which describes how better tools and approaches may finally bridge discovery and clinical trials. Authored by award-winning editor-in-chief, Malorye Allison
Branca, the feature provides detailed insight from leading pharmaceutical companies on technologies and strategies that may allow them to predict a drug failure earlier in the development cycle, and ensure greater success of those that go on to clinical trials. (See release issued May 24 – “Pharmaceutical companies are pushing many more candidate drugs into early stage trials, but will that be enough to cure the product drought? Proof-of-concept may be the answer.”). Ms. Branca is a widely-published science writer and editor. Previously, she launched the Spectrum Drug Discovery and Development portfolio at Decision Resources, and CHI’s Advances reports series, which focuses on novel discovery and development tools. She has also launched multiple health related magazines.
About Pharma DD
Pharma DD, published 6x per year, provides senior researchers and scientific management with unique insight into the industry-leading techniques and approaches driving new therapeutic discovery and development. As well as focusing on business issues, regulatory considerations, clinical trials, and post-approval safety issues. The publication and accompanying web site
www.pharmaDD.com, deliver features, news, commentaries, and case studies to professionals in
pharma, biotech, and research laboratories. Pharma DD is published by Cambridge Healthtech Institute, based in Newton Upper Falls, MA.
About
Pharma DD
Pharma DD, published 6x per year, provides senior
researchers and scientific management with unique
insight into the industry-leading techniques and
approaches driving
new therapeutic discovery and development. As well as
focusing on business issues, regulatory
considerations, clinical trials, and post-approval
safety issues. The publication and accompanying web
site www.pharmaDD.com,
deliver features, news, commentaries, and case studies
to professionals in pharma, biotech, and research
laboratories. Pharma DD is published by Cambridge
Healthtech Institute, based in Newton Upper Falls, MA
About
Cambridge Healthtech Institute
CHI’s renowned conferences are the underpinning for
all our other information resources. Each year, CHI
organizes over 80 conferences held throughout the US.
including The
Molecular Medicine Tri-Conference, Beyond
Genome, PepTalk,
World
Pharmaceutical Congress and the new acquired
Bio-IT World’s Life Sciences Conference & Expo.
The company strives to develop quality programs
that provide valuable new insights and competing
points of view while offering balanced coverage of the
latest developments. Basic research related to
commercial implications is covered, with heavy
emphasis placed on end-user insights into new products
and technology as well as coverage on the strategy
behind the business. Leading researchers and business
experts from top pharmaceutical, biotech and academic
organizations present their most current findings in a
forum that features panel discussions and audience
participation. Over the past 14 years, CHI has
produced more than 400 conferences, attracting more
than 50,000 attendees from around the world.
In
addition to CHI’s vast conference portfolio, their
media properties include PharmaWeek,
available on the web only, Pharma
DD, and Bio-IT
World, Inc.
For more information, contact:
Malorye Allison Branca
Editor-in-Chief
978-264-0758
editor@pharmadd.com
Press Contact :
Lisa Scimemi
Cambridge Healthtech Institute
Ph. (617) 630-1319
lscimemi@healthtech.com
|
